Fig. 2
From: TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
Comparison on copy number variants (CNVs) between TET1-mutated and wild-type patients in the non-ICI-treated cohort. A CNV status in COAD. B CNV status in TET1-mutated patients. C CNV status in TET1 wild-type patients